Phase II data investigating ramucirumab with paclitaxel/carboplatin as first-line therapy for stage IIIB/IV NSCLC revealed 6-month progression free survival ...

Phase II data investigating ramucirumab with paclitaxel/carboplatin as first-line therapy for stage IIIB/IV NSCLC revealed 6-month progression free survival ... Cytotoxic chemotherapy · Immunotherapeutic targets

The most commonly used regimens are carboplatin and paclitaxel, carboplatin and protein-bound paclitaxel (nab-paclitaxel), and cisplatin and gemcitabine.

›Initiation of erlotinib after 4–6 cycles of first-line platinum-doublet chemotherapy (category 2B). ›Initiation of docetaxel after 4–6 cycles of first-line ...

It's a type of non-small cell lung cancer (NSCLC) that typically is treated using one or more types of therapy—surgery, radiation, chemotherapy, angiogenesis ...

Pembrolizumab In Combination with CARBOplatin and PACLitaxel for the first-line treatment of Patients with metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) ...

17 мая 2019 г. · Pembrolizumab monotherapy (PD-L1 TPS ≥ 50%) and carboplatin plus taxane plus pembrolizumab combinatorial therapy are new first-line standards of care.

The SQUIRE trial regimen consisted of gemcitabine 1250 mg/m2 on days 1 and 8 plus cisplatin at 75 mg/m2 on day 1 with necitumumab (n = 545) or placebo (n = 548) ...

Paclitaxel + carboplatin9. Day 1: Paclitaxel 200mg/m2 IV + carboplatin AUC 6mg • min/mL IV. Repeat cycle every 3 weeks for 4 cycles. Chemotherapy Regimens Used ...